跳至主要内容
临床试验/NCT05386277
NCT05386277招募中不适用

A Post Market Clinical Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter on Patients Undergoing Surgical Treatment for the Removal of Arterial Emboli and/or Thrombi

LeMaitre Vascular3 个研究点 分布在 3 个国家目标入组 112 人开始时间: 2022年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
112
试验地点
3
主要终点
Safety objective is defined as acceptable safety outcomes (e.g. (Serious) Device and/or Procedure Related Events) during the procedure

研究概览

简要总结

A post market clinical study to confirm the performance and safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter on patients undergoing surgical treatment for the removal of arterial emboli and/or thrombi

详细描述

This prospective, single arm, post market clinical study was designed to proactively collect clinical data on the LeMaitre® TufTex Single Lumen Embolectomy Catheters and to confirm its performance in removing arterial emboli and/or thrombi, to identify and analyze emergent risks on the basis of factual evidence, and to ensure the continued acceptability of the benefit/risk ratio. This post market study is sponsored by LeMaitre® Vascular, Inc., the manufacturer of the device. Study will take place at 3 to 8 sites in Europe, the target sample size is 112 patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subject, ≥ 18 years of age at time of enrollment.
  • Subject who is scheduled to undergo surgical treatment for the removal of arterial or venous emboli and/or thrombi, where one of the LeMaitre® Embolectomy Catheter will be used.
  • Subject signed an Informed Consent for participation.
  • Subject diagnosed with a embolus/thrombus.
  • Subjects for whom thrombolytic therapy had failed or was contraindicated.

排除标准

  • Co-morbidity that in the discretion of the investigator might confound the results.
  • Subjects who are unable to read or write.
  • Pregnant or lactating women at time of enrollment
  • Subjects who are immune comprised

结局指标

主要结局

Safety objective is defined as acceptable safety outcomes (e.g. (Serious) Device and/or Procedure Related Events) during the procedure

时间窗: During procedure and 1 month post index procedure

The primary safety objective is defined as acceptable safety outcomes (e.g. (Serious) Device and/or Procedure Related Events) during the procedure and 1 Month post index procedure.

Performance objective is the technical success as defined as <30% residual stenosis

时间窗: 1 month post index procedure

The primary performance objective is the technical success as defined as \<30% residual stenosis of the target vessel.

次要结局

  • 2. Revision Rate(1 month post index procedure)
  • 1. Clinical success(1 Month after the index procedure)
  • 4. Secondary Patency(1 month post index procedure)
  • 3. Primary Assisted Patency(1 month post index procedure)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

A PMCF Study to Confirm the Performance and Safety... | 临床试验